HIGHFDA DRUG

Glenmark Theophylline Extended-Release 400mg Recall Expanded for Failed Dissolution Tests (2025)

Glenmark Pharmaceuticals Inc. USA recalls theophylline extended-release 400 mg tablets after dissolution test failures. The recall covers 22,656 bottles distributed nationwide in the United States. Consumers should stop using the product and contact Glenmark for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
August 8, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
August 8, 2025
Hazard Level
HIGH
Brands
Glenmark Pharmaceuticals Inc., THEOPHYLLINE
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PREGNANT

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Glenmark Pharmaceuticals Inc., THEOPHYLLINE
Product type
Theophylline extended-release tablets
Model numbers
Batch # 19243193, 19243215, 19243231, 19243248, 19243283, 19244530, 19244561, 19250178
UPC codes
68462-356, 68462-380, 68462-380-01, 68462-380-05, 68462-356-01, 68462-356-05
Sizes
100-count bottle
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    August 8, 2025

  2. Reported by FDA DRUG

    August 20, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter

About This Product

Theophylline extended-release tablets are used to treat certain respiratory conditions by maintaining steady theophylline levels in the body.

Why This Is Dangerous

Dissolution failures may lead to inconsistent drug release, potentially affecting therapeutic effectiveness.

Industry Context

This recall is not identified as part of a broader industry pattern in the provided data.

Real-World Impact

Consumers may experience reduced or inconsistent medication effectiveness, requiring clinician guidance.

Practical Guidance

How to identify if yours is affected

  1. Verify 100-count bottle packaging

Where to find product info

NDC on the bottle label and packaging; recall page for enforcement details

What timeline to expect

Refund or replacement processing timelines are not specified in the data; contact manufacturer for guidance

If the manufacturer is unresponsive

  • File a consumer complaint with the FDA via MedWatch
  • Seek guidance from your pharmacist or healthcare provider
  • Document all communication and keep packaging for reference

How to prevent similar issues

  • Always verify NDC and batch numbers when receiving prescriptions
  • Report any loss of efficacy or unusual symptoms to a clinician promptly
  • Request replacement product when undergoing recall

Documentation advice

Keep bottle, UPCs, label, batch numbers, and recall notice for records

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Brand: Glenmark Pharmaceuticals Inc. USA. Product: Theophylline extended-release tablets 400 mg, Rx only. NDC: 68462-380-01. Form: 100-count bottle. Batch numbers include 19243193, 19243215, 19243231, 19243248, 19243283, 19244530, 19244561, 19250178. Manufactured by Glenmark Pharmaceuticals Limited, Colvale-Bardez, Goa, India. Distributed nationwide in the USA. Recall date: 2025-08-08. Status: Active. Quantity: 22,656 bottles.

Reported Incidents

No specific injuries or incidents are reported in the provided data.

Key Facts

  • Dissolution failure found in UV dissolution tests
  • Active recall as of 2025-08-08
  • Distributed nationwide in the USA

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPREGNANTPETS
Injury Types
OTHER

Product Details

Model Numbers
Batch # 19243193
19243215
19243231
19243248
19243283
+3 more
UPC Codes
68462-356
68462-380
68462-380-01
+3 more
Affected States
ALL
Report Date
August 20, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls